{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-270275","form_type":"8-K","ticker":"LXEO","cik":"0001907108","company_name":"Lexeo Therapeutics, Inc.","filed_at":"2026-06-15T11:05:59+00:00","discovered_at":"2026-06-15T11:10:00.439540+00:00","generated_at":"2026-06-15T11:10:36.108019+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Lexeo finalizes SUNRISE-FA 2 pivotal trial for LX2006 in FA cardiomyopathy; BLA submission expected H1 2028","bullets":["Open-label pivotal trial of LX2006: 13 treated vs 13 untreated control; primary endpoint LVMI at 6 months.","BLA submission under accelerated approval on track for H1 2028; topline data readout expected H2 2027.","FDA removed co-primary endpoint of cardiac frataxin protein expression; trial powered for LVMI effect size ≥15%.","Pediatric cohorts included; untreated control participants eligible to cross over to LX2006 after 6 months.","CLARITY-FA natural history study ongoing, shares inclusion criteria; first patient enrollment by end of June 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-270275","json":"https://secwatch.observer/filing/0001193125-26-270275.json","markdown":"https://secwatch.observer/filing/0001193125-26-270275.md","text":"https://secwatch.observer/filing/0001193125-26-270275.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1907108/000119312526270275/0001193125-26-270275-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1907108/000119312526270275/lxeo-20260615.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T11:10:36.108019+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}